Novo Nordisk's $9bn Bid for Metsera Sparks Pharma Rivalry

In a surprising move within the pharmaceuticals industry, Novo Nordisk has announced a bid of $9 billion (£6.9 billion) for the US-based biotech company Metsera, a significant player in the obesity treatment sector. This offer comes as a direct challenge to Pfizer, which recently placed its own $7.3 billion bid for Metsera, intensifying the battle between these pharmaceutical giants for supremacy in the weight-loss market.

Just weeks ago, Metsera had accepted a takeover offer from Pfizer, marking a pivotal moment in the ongoing competition for leadership in the obesity treatment arena. Novo Nordisk, a Danish company renowned for its successful weight-loss drugs, Ozempic and Wegovy, had previously participated in a competitive auction process in September but did not secure the winning bid.

Pfizer swiftly criticized Novo Nordisk's unsolicited offer, labeling it as a "reckless" move aimed at suppressing competition. The company asserted that this action violates antitrust laws, framing it as an attempt by a market-dominant player to eliminate an emerging American competitor. Pfizer has now been given a window of just four business days to enhance its offer for Metsera, which made its debut on the Nasdaq index earlier this year.

Metsera has emerged as an attractive acquisition possibility, largely due to its promising lineup of obesity treatments. The biotech firm is currently conducting four clinical trials, which include:

Researchers are optimistic that amylin could mitigate the muscle loss commonly associated with existing weight-loss medications, making Metsera an even more appealing target for acquisition.

In its proposal, Novo Nordisk has offered $56.50 per share for Metsera, which translates to an approximate valuation of $6.5 billion. Furthermore, the Danish company has included an additional $21.25 per share, amounting to about $2.5 billion, contingent on Metsera achieving specific clinical and regulatory milestones.

In a formal statement, Novo Nordisk emphasized that acquiring Metsera would align with its long-term strategy of developing innovative medications aimed at treating millions of individuals affected by obesity and diabetes, along with their related comorbidities.

Conversely, Metsera has publicly declared that Novo Nordisk's bid is "superior" to Pfizer's existing offer, which stands at $47.50 per share, plus an additional $22.50 for meeting further milestones. However, Pfizer has dismissed the notion that Novo Nordisk's bid is superior, characterizing it as "illusory" and asserting that the structure of the offer is designed to "circumvent antitrust laws," carrying substantial risks related to regulatory approval and implementation.

Pfizer has made it clear that it is prepared to explore all legal avenues to protect its interests under the current agreement with Metsera, underscoring the contentious nature of this bidding war.

As Novo Nordisk pursues this aggressive strategy, it faces challenges of its own, including a deceleration in profit growth and a decline in its stock price. These issues have been exacerbated by increased competition from its US rival, Eli Lilly, which produces the weight-loss medications Mounjaro and Zepbound. Clinical studies have indicated that Mounjaro may outpace Wegovy in terms of weight-loss efficacy.

In light of this competitive landscape, Eli Lilly recently adjusted its full-year revenue guidance upward, following stronger-than-expected earnings in the third quarter from its weight-loss and diabetes drugs. The company is also preparing to submit its own weight-loss pill to regulatory authorities by the end of the year.

The escalating bids for Metsera illustrate the intense rivalry within the pharmaceuticals industry, especially in the lucrative weight-loss market. As Novo Nordisk and Pfizer continue to vie for control, the outcome of this bidding war could have significant implications for the future of obesity treatments and the companies involved. With ongoing clinical trials and innovative drug pipelines, the stakes are high for all parties, and the next few weeks will be crucial in determining how this competition unfolds.